Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ralph Lauren Corp (RL) vs ResMed Inc. (RMD) Price & Performance

Ralph Lauren CorpTrade
ResMed Inc.Trade

Price performance (Past 24H)

Key statistics

Ralph Lauren Corp vs ResMed Inc. — how do they compare? Ralph Lauren Corp trades at $340.2 (market cap $20.69B), while ResMed Inc. trades at $219.5 (market cap $31.89B). The key difference: ResMed Inc. is the larger of the two by market cap, and ResMed Inc. pays the higher dividend (1.19%). Which is the better fit depends on your goals.

RLRMD
Market Cap
$20.69B$31.89B
Sector
Consumer CyclicalHealth
52-Week High
$414.25$283.28
52-Week Low
$302.89$182.82
Enterprise Value
$21.75B$31.24B
Dividend Yield
1.15%1.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ralph Lauren Corp

Ralph Lauren (RL) trades at $347.23, down 1.13% on the day, with the stock showing bearish technical signals despite strong fundamentals. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $4.59 surpassing the $4.32 estimate. Revenue growth has accelerated from $6.2B in 2022 to $7.1B in 2025, while net income margins improved to 10.49%. Recent corporate developments include a new cancer center partnership in South Korea and ongoing AI investments to enhance customer experience.

The investment outlook remains positive with 66% analyst buy ratings and a $456.50 consensus price target representing 31% upside potential. However, the stock faces near-term technical pressure with bearish moving averages and faces execution risks in maintaining luxury brand positioning amid economic uncertainty. Strong profitability metrics including 37.54% ROE and improving cash flow generation support the long-term growth thesis.

ResMed Inc.

ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.

The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.

Returns comparison

Trailing returns across standard periods

About Ralph Lauren Corp

Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.

Read more on RL

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD